Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
June 26 2023 - 7:01AM
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare
company, today announced that Twirla will become available to MMCAP
Infuse Members effective July 1, 2023. The Company expects this
increased availability to positively impact growth of demand and
factory sales in the non-retail channel, which grew 20% and 15%
respectively from the fourth quarter 2022 to first quarter 2023.
“We expect to see accelerated growth in the
Twirla non-retail channel by partnering with MMCAP Infuse, a
national cooperative GPO for government facilities that provides
contracts for healthcare products and services, including birth
control products,” said Agile Therapeutics’ Chief Commercial
Officer Amy Welsh.
MMCAP Infuse has over 26,000 member facilities
in all 50 states, including state agencies, counties, cities, and
school districts,. This partnership with MMCAP Infuse reinforces
Agile’s commitment to making Twirla available to as many patients
as possible.
Agile continues to prioritize strategic
partnerships that have the potential to efficiently and effectively
grow Twirla while simultaneously allowing the Company to
responsibly manage its operating expenses.
About Agile
Therapeutics, Inc.Agile
Therapeutics is a women's healthcare company dedicated to
fulfilling the unmet health needs of today’s women. Our product and
product candidates are designed to provide women with contraceptive
options that offer freedom from taking a daily pill, without
committing to a longer-acting method. Our initial product, Twirla®,
(levonorgestrel and ethinyl estradiol) transdermal system is a
non-daily prescription contraceptive. Twirla is based on our
proprietary transdermal patch technology, called Skinfusion®, which
is designed to allow drug delivery through the skin. For more
information, please visit the company website at
www.agiletherapeutics.com. The Company may
occasionally disseminate material, nonpublic information on the
Company’s website, Twitter account (@agilether), and LinkedIn
account.
About Twirla®
Twirla (levonorgestrel and ethinyl estradiol)
transdermal system is a once-weekly combined hormonal contraceptive
(CHC) patch that contains the active ingredients levonorgestrel
(LNG), a type of progestin, and ethinyl estradiol (EE), a type of
estrogen. Twirla is indicated for use as a method of contraception
by women of reproductive potential with a body mass index (BMI)
< 30 kg/m2 for whom a combined hormonal contraceptive is
appropriate. Healthcare providers (HCPs) are encouraged to consider
Twirla’s reduced efficacy in women with a BMI ≥ 25 to <30 kg/m2
before prescribing. Twirla is contraindicated in women with a BMI ≥
30 kg/m2. Twirla is also contraindicated in women over 35 years old
who smoke. Cigarette smoking increases the risk of serious
cardiovascular events from CHC use. Twirla is designed to be
applied once weekly for three weeks, followed by a week without a
patch.
Forward-Looking
StatementsCertain information contained in this
press release includes “forward-looking statements”, within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
We may, in some cases use terms such as “predicts,” “believes,”
“potential,” “continue,” “anticipates,” “estimates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “likely,” “will,”
“should” or other words that convey uncertainty of the future
events or outcomes to identify these forward-looking statements.
Our forward-looking statements are based on current beliefs and
expectations of our management team that involve risks, potential
changes in circumstances, assumptions, and uncertainties, including
statements regarding expected Twirla demand and growth metrics, our
projected net revenue and expected operating expenses for 2023, our
ongoing and planned manufacturing and commercialization of Twirla®,
the potential market acceptance and uptake of Twirla, including the
increasing demand for Twirla in 2023, our partnership with MMCAP
Infuse and its ability to promote growth, and the availability of
Twirla through MMCAP Infuse, and the associated increase in demand
for Twirla. Any or all of the forward-looking statements may turn
out to be wrong or be affected by inaccurate assumptions we might
make or by known or unknown risks and uncertainties. These
forward-looking statements are subject to risks and uncertainties
including risks related to the fact that our projected Twirla
demand and growth, net revenue, and operating expenses for 2023 may
be incorrect, our ability to maintain regulatory approval of Twirla
and the labeling under any such approval, our ability to
successfully enhance the commercialization of and increase the
uptake for Twirla, the size and growth of the markets for Twirla
and our ability to serve those markets, regulatory and legislative
developments in the United States and foreign countries, our
ability to obtain and maintain intellectual property protection for
Twirla, and the other risks set forth in our filings with the U.S.
Securities and Exchange Commission, including our Annual Report on
Form 10-K and our Quarterly Reports on Form 10-Q. For all these
reasons, actual results and developments could be materially
different from those expressed in or implied by our forward-looking
statements. You are cautioned not to place undue reliance on these
forward-looking statements, which are made only as of the date of
this press release. We undertake no obligation to publicly update
such forward-looking statements to reflect subsequent events or
circumstance.
Contact:Matt RileyHead of Investor Relations
& Corporate
Communicationsmriley@agiletherapeutics.com
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Apr 2024 to May 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From May 2023 to May 2024